Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
Open Access
- 16 December 2009
- journal article
- review article
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 28 (3-4) , 305-316
- https://doi.org/10.1007/s10555-009-9198-3
Abstract
The phosphatidylinositol 3-kinase (PI3K) pathway is a critical signal transduction pathway that regulates multiple cellular functions. Aberrant activation of this pathway has been identified in a wide range of cancers. Several pathway components including AKT, PI3K and mTOR represent potential therapeutic targets and many small molecule inhibitors are in development or early clinical trials. The complex regulation of the pathway, together with the multiple mechanisms by which it can be activated, make this a highly challenging pathway to target. For successful inhibition, detailed molecular information on individual tumours will be required and it is already clear that different tumour types show distinct combinations of alterations. Recent results have identified alterations in pathway components PIK3CA, PTEN, AKT1 and TSC1 in bladder cancer, some of which are significantly related to tumour phenotype and clinical behaviour. Co-existence of alterations to several PI3K pathway genes in some bladder tumours indicates that these proteins may have functions that are not related solely to the known canonical pathway.Keywords
This publication has 89 references indexed in Scilit:
- Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific mannerOncogene, 2009
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- Missense mutations to the TSC1 gene cause tuberous sclerosis complexEuropean Journal of Human Genetics, 2008
- PI3K pathway alterations in cancer: variations on a themeOncogene, 2008
- Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanismsHuman Molecular Genetics, 2008
- Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanismsProceedings of the National Academy of Sciences, 2008
- Distinctive Expression Pattern of ErbB Family Receptors Signifies an Aggressive Variant of Bladder CancerJournal of Urology, 2008
- Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation patternProceedings of the National Academy of Sciences, 2007
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007
- The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patientsBritish Journal of Cancer, 2006